References
- Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–6
- Khosravi-Far R, Der CJ. The ras signal transduction pathway. Cancer Metastasis Rev 1994; 13: 67–89
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90
- Cheng AYK, Chen Z, Tsao C, Qin S, Kim J, Burock K, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008; 26: 4509, (Abstract)
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–80
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39
- Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the raf/mek/erk pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model plc/prf/5. Cancer Res 2006; 66: 11851–8
- Meyer RD, Qian X, Guo HC, Rahimi N. Leucine motif-dependent tyrosine autophosphorylation of type III receptor tyrosine kinases. J Biol Chem 2006; 281: 8620–7
- Kim, RD, Lazaryan, A, Aucejo, F, Eghtesad, B, Pelley, R, Fung, J, , et al. Vascular endothelial growth factor receptor 2 (vegfr2) expression and recurrence of hepatocellular carcinoma following liver transplantation: The Cleveland Clinic experience. J Clin Oncol 2008;26.
- Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004; 29: 113–21
- Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived growth factor receptor-alpha: A novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007; 6: 1932–41